Effect of niacin and etofibrate association on subjects with coronary artery disease and serum high-density lipoprotein cholesterol <35 mg/dl

Am J Cardiol. 1999 Jan 1;83(1):98-100, A8. doi: 10.1016/s0002-9149(98)00787-5.

Abstract

Niacin treatment (alone) was compared with etofibrate and niacin combination to treat patients with high-density lipoprotein <35 mg/dl and without hypertriglyceridemia. The niacin and etofibrate combination proved to be safe and increased high-density lipoprotein cholesterol levels to 48%, which was 3 times higher than that obtained with niacin alone.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Anticholesteremic Agents / administration & dosage
  • Anticholesteremic Agents / therapeutic use*
  • Cholesterol, HDL / blood*
  • Clofibric Acid / administration & dosage
  • Clofibric Acid / analogs & derivatives*
  • Clofibric Acid / therapeutic use
  • Coronary Disease / blood
  • Coronary Disease / drug therapy*
  • Delayed-Action Preparations
  • Drug Administration Schedule
  • Drug Synergism
  • Female
  • Humans
  • Lipids / blood
  • Male
  • Middle Aged
  • Niacin / administration & dosage
  • Niacin / therapeutic use*
  • Time Factors
  • Treatment Outcome

Substances

  • Anticholesteremic Agents
  • Cholesterol, HDL
  • Delayed-Action Preparations
  • Lipids
  • etofibrate
  • Niacin
  • Clofibric Acid